Improvements in asthma care will have to be made
through better inhalers not new drugs, according
to one of the UK's leading asthma experts.
- European Respiratory Society
Meeting, 2005
Our focus is on developing aerosol therapies
that fulfill an unmet or undermet patient need
and provide a “leap” in value, not just and
incremental step. Throughout all our projects,
we ask ourselves:
-
How can we improve compliance and quality of
life?
-
Can we improve disease control or prevent
symptoms?
-
How can we reduce patient exposure to
medication while still achieving the desired
efficiacy and safety profiles?
-
How can we minimize unwanted side effects?
How can we improve long term safety?
In working to reach these goals, we have two
distinct business models—a Partner Pipeline and
our PARI Pipeline.
In our Partner Pipeline, we work together with
pharmaceutical partners interested in
developing
treatments aimed at answering the questions
above. We
enter into a licensing agreement for both device
and formulation technology and both companies
develop therapies as a comprehensive project. |
 |
| |
|
|
Our Pipeline develops its own therapies
where the formulation is optimized to the
device. We manage all aspects of development
including clinical, regulatory and commercial
functions. We pursue these programs in selected
markets where there appears to be little or no
real interest from pharmaceutical companies.
|
 |
|
